Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for a variety of malignant and nonmalignant hematologic disorders. Unfortunately, only about a third of candidates for alloHSCT have HLA-matched siblings. Haploidentical alloHSCT with post-transplant cyclophosphamide has become a safe and effective procedure for patients without an HLA-matched donor, either related or unrelated. Advantages over other unrelated sources include rapid availability of multiple potential donors, lower costs of graft acquisition, non-inferiority in tumor control and low incidence of chronic GvHD. 1 In this report, we present a case of a patient with paroxysmal nocturnal hemoglobinuria (PNH) and severe aplastic anemia without response to eculizumab who was treated with a haploidentical alloHSCT with post-transplant cyclophosphamide with excellent hematological outcome and quality of life.
A 22-year-old man was hospitalized due to fatigue and pallor in November 2012. CBC showed severe and progressive pancytopenia (900 leukocytes/μL, 200 neutrophils/μL, 8 gr hemoglobin/dL with 0.2% reticulocytes and 25 000 platelets/μL), with elevated lactate dehydrogenase and suppressed haptoglobin levels. A bone marrow biopsy showed mild hypoplasia with cellularity between 10 and 50%. Peripheral blood flow cytometry showed a PNH clone (CD16 − , CD55 − and CD59 − ) in 5% of erythrocytes, 12% of monocytes and 5% of granulocytes. A new flow cytometric analysis 2 years later showed a PNH clone in 26% of erythrocytes and 72% of monocytes. Constitutional symptoms appeared in the meantime. Eculizumab treatment was initiated at a dose of 600 mg weekly for four doses and then 900 mg every other week. After 2 months of treatment, there was no clinical improvement; however, there was a significant decrease in the lactate dehydrogenase levels, although not to a normal value. We increased eculizumab dose to 1200 mg every other week for 2 months, without any further clinical response. Along with eculizumab, cyclosporine was added with the dose adjusted to maintain serum levels between 250 and 500 ng/μL, but no cell count improvement was observed. The patient had no siblings and unrelated donor search did not identify a suitably matched donor. Hence, we selected his father as a HLA 3/6-compatible haploidentical donor.
After a conditioning regimen of IV cyclophosphamide 14.5 mg/kg per day on days − 6 and − 5 (total dose 1960 mg) with equivalent doses of mesna, IV fludarabine 30 mg/m 2 per day on days − 6 to − 2 (total dose 250 mg) and 200 cGy of TBI on day − 1, the patient received 5.45 × 10 6 /kg CD34+ G-CSF-mobilized peripheral blood hematopoietic cells. GvHD prophylaxis included cyclophosphamide 50 mg/kg per day on days +3 and +4 with mesna equivalent dose, tacrolimus between days +5 and +180 to achieve levels between 5 and 15 ng/μL, and mycophenolate mofetil between days +5 and +35. Prophylactic antimicrobial therapy was started on day − 6 and included levofloxacin 500 mg PO daily, fluconazole 200 mg PO daily and acyclovir 400 mg PO thrice daily; Pneumocystis carinii prophylaxis with trimethoprimsulfamethoxazole was started when granulocyte engraftment was achieved. The period of aplasia was well tolerated with a brief episode of febrile neutropenia without microbiological isolation. He achieved neutrophil and platelet engraftment on days +15 and +17, respectively, and was discharged on day +18 after his transplant. The patient did not develop acute or chronic GvHD. On day +51, he presented with asymptomatic reactivation of CMV that was treated with valganciclovir. Peripheral blood chimerism showed stable and prolonged 495% donor engraftment from day +30. No evidence of PNH was found on peripheral blood flow cytometry analysis performed on days +30, +120, +270 and +318. Clinical recovery was satisfactory, achieving normal quality of life. Nine months after transplantation, blood counts are normal, without evidence of PNH, persistent 495% donor chimerism, and without any chronic GvHD. His only complication after transplantation was Pneumocystis jerovecii pneumonia on day +261 due to his decision to discontinue trimethoprim-sulfamethoxazole primary prophylaxis, but was successfully treated with oral trimethoprim-sulfamethoxazole and currently is on secondary prophylaxis (Figure 1 ).
Eculizumab is a humanized monoclonal Ab that inhibits the formation of C′ proteins and is the only drug approved for treatment of PNH.
2 Eculizumab is highly effective in stopping intravascular hemolysis and reducing the transfusion rate in 70% of patients, with overall survival equivalent to the population without PNH.
3 Unfortunately in some patients such as ours, eculizumab does not control the symptoms, possibly due to genetic variants although this is very rare. 4 The Johns Hopkins transplantation group has previously shown their experience with haploidentical transplantation in non-malignant hematological patients, with very good rates of overall and disease-free survival. 1, 5 In particular, they reported three patients with PNH who had survived with this transplant approach; however, all their patients were treated in the pre-eculizumab era.
6 There are few reports on haploidentical transplantation with post-transplant cyclophosphamide in aplastic anemia. [7] [8] [9] As far as we know, our case is the first that shows a patient with PNH and secondary aplastic anemia who achieved a prolonged disease-free state with haploidentical reduced intensity transplantation. In PNH patients who require an allogeneic transplant but do not have a fully matched related or unrelated donor, a haploidentical reduced intensity transplant may be an acceptable option. This is especially relevant in countries underrepresented in international donor registries, where an unrelated donor can be identified for only around a third of all patients. In other diseases like acute myeloid leukemia, haploidentical transplantation has become an accepted procedure with comparable results to related and unrelated donors, 10, 11 and it is likely that this source of hematopoietic cells could be used in other diseases, like PNH. Letter to the Editor
